Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Denmark approves compensation for four patients with rare eye condition linked to Ozempic and Wegovy.
Denmark has approved compensation for four people who developed a rare, permanent eye condition linked to weight-loss and diabetes drugs Ozempic and Wegovy, made by Novo Nordisk.
The Danish Patient Compensation Association awarded 800,000 kroner ($123,000) to the patients, citing preliminary evidence of a connection despite NAION being classified as a very rare side effect—up to 1 in 10,000 users.
The decision, based on five assessed cases among over 40 applications, marks the first such approvals.
The European Medicines Agency confirmed the rare risk and recommended updated warnings.
Novo Nordisk maintains the drugs’ benefits outweigh risks and has updated safety information.
Compensation may increase if long-term disability or lost income is confirmed.
Dinamarca aprueba la compensación de cuatro pacientes con una enfermedad ocular rara relacionada con Ozempic y Wegovy.